title: Angiogenesis and cardioprotection after TNFalpha-inducer-Tolpa Peat Preparation treatment in rat's hearts after experimental myocardial infarction in vivo.
abstract: The aim of the presented work was to evaluate whether short subcutaneous (s.c.) administration of TNFalpha-inducer-Tolpa Peat Preparation (TPP or TPP batch 0210) modulates the process of ischemic remodeling and spontaneous angiogenesis after experimental myocardial infarction (MI) in rats in vivo. The results obtained using three complementary and correlative methods: histological studies, Proliferating Cell Nuclear Antigen (PCNA) reaction and Lymphocytes Induced Angiogenesis (LIA) test showed a clear pro-angiogenic and cardioprotective effect of TPP administration after experimental MI. TPP batch 0210 should be considered as an angiogenesis stimulating factor and consecutively as a cardioprotective preventing development of ischemic cardiomyopathy after MI in rats. It might possibly be used as an adjunct to conventional therapy of coronary artery disease, including late phase after myocardial infarction or ischemic cardiomyopathy.
authors.affiliation: Department of Pharmacology, Medical University of Silesia, 41-808 Zabrze, Jordana 38, Poland. tadkrzem@ka.onet.pl
authors.forename: Tadeusz F
authors.initials: TF
authors.lastname: Krzemiński
authors.forename: Jerzy K
authors.initials: JK
authors.lastname: Nozyński
authors.forename: Joanna
authors.initials: J
authors.lastname: Grzyb
authors.forename: Maurycy
authors.initials: M
authors.lastname: Porc
authors.forename: Sławomir
authors.initials: S
authors.lastname: Zegleń
authors.forename: Violetta
authors.initials: V
authors.lastname: Filas
authors.forename: Ewa
authors.initials: E
authors.lastname: Skopińska-Rózewska
authors.forename: Ewa
authors.initials: E
authors.lastname: Sommer
authors.forename: Małgorzata
authors.initials: M
authors.lastname: Filewska
mesh_terms: D000596:Amino Acids / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D000818:Animals; D002241:Carbohydrates / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D002316:Cardiotonic Agents / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D004195:Disease Models, Animal; D004338:Drug Combinations; D006812:Humic Substances; D007150:Immunohistochemistry; D007279:Injections, Subcutaneous; D008297:Male; D009203:Myocardial Infarction / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D009206:Myocardium / Q000378:metabolism / Q000473:pathology; D018919:Neovascularization, Physiologic / Q000187:drug effects*; D051381:Rats; D017207:Rats, Sprague-Dawley; D014409:Tumor Necrosis Factor-alpha / Q000096:biosynthesis*; D014574:Uronic Acids / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D020257:Ventricular Remodeling / Q000187:drug effects
chemical_list: D000596:Amino Acids; D002241:Carbohydrates; D002316:Cardiotonic Agents; D004338:Drug Combinations; D006812:Humic Substances; C084029:Tolpa; D014409:Tumor Necrosis Factor-alpha; D014574:Uronic Acids